FINWIRES · TerminalLIVE
FINWIRES

Invivyd Completes Enrolment in Phase 3 Symptomatic COVID-19 Trial

By

Invivyd (IVVD) said Monday that it has completed patient enrolment in the phase 3 Declaration trial, evaluating its VYD2311 antibody for the prevention of symptomatic COVID-19.

Top-line results from the study are still expected in late Q3, the company said.

The Declaration study is evaluating the prevention of symptomatic COVID-19 at three months, with either a single dose or monthly doses of VYD2311, administered via intramuscular injection, compared to placebo, Invivyd said.

Shares of the company were up 2.6% in Monday's premarket activity.

Price: $1.17, Change: $+0.03, Percent Change: +2.63%

Related Articles

Wire

Robo.ai Completes Acquisition of Neurovia AI; Shares Up Pre-Bell

Robo.ai (AIIO) shares were up 36% in Monday's premarket activity after the company said it has completed the acquisition of Neurovia AI.Neurovia AI, a visual data processing and compression technology company, plans to advance the commercialization of its platform through data infrastructure licensing, enterprise-level SaaS, and smart city solutions, Robo.ai said.Financial terms of the acquisition were not disclosed.Price: $3.24, Change: $+0.86, Percent Change: +36.29%

$AIIO
Wire

HPE Expands Server Portfolio With Nvidia Processors

Hewlett Packard Enterprise (HPE) said Monday it expanded its server portfolio with the release of the ProLiant Compute DL394 Gen12 using Nvidia (NVDA) Vera processors.The hardware is engineered to support high-performance artificial intelligence and data processing applications, the company said.The device uses a monolithic chip design and high-efficiency memory to avoid calculation delays, and integrates quantum-resistant security protocols and unified management software to automate operations, HPE said.The product will be available by the end of the year and is offered through a corporate financing plan, it added.Shares of HPE were up over 6% in Monday premarket activity.Price: $45.86, Change: $+2.80, Percent Change: +6.50%

$HPE$NVDA
Wire

Replimune Says Evaluating RP2 for Metastatic Uveal Melanoma in Phase 2/3 Trial; Shares Up Pre-Bell

Replimune (REPL) said Sunday it is now evaluating RP2 in combination with nivolumab for metastatic uveal melanoma in a phase 2/3 trial based on results from the phase 1 trial.The company said in its phase 1 first-in-human trial, RP2 monotherapy achieved an objective response rate of 19% in patients with advanced solid tumors. RP2 in combination with nivolumab had an objective response rate of 19.1%, it said.In uveal melanoma, the pooled objective response rate, which included RP2 in combination with nivolumab and RP2 monotherapy, was 33.3%, it said.The phase 1 first-in-human trial had enrolled 85 heavily pretreated patients with advanced solid tumors, including uveal melanoma, colorectal cancer, head and neck cancers, pancreatic cancer, cutaneous melanoma, and sarcoma, the company said.Shares of the company were up over 13% in Monday's premarket activity.Price: $9.90, Change: $+1.21, Percent Change: +13.92%

$REPL